• Hero Banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Top Recommended Veterinary Products
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Buying or Selling a Practice
Hospital Design
Leadership & Personal Growth
Personnel Management
Practice Finances
Practice Operations
Technology
Wellbeing & Lifestyle
Continuing Education
Conferences
Live Conferences
Conference News
Conference Proceedings
Resources
CBD in Pets
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Noteworthy FDA Approvals

July 2, 2018
American Veterinarian Staff
American Veterinarian, July 2018, Volume 3, Issue 5

Did you miss the announcements of these 3 new feline drugs?

Centragard (eprinomectin and praziquantel transdermal solution)—manufactured by Merial, now a part of Boehringer Ingelheim—is indicated for the prevention of heartworm disease caused by Dirofilaria immitis. It is also approved for the treatment and control of roundworms (adult and fourth-stage larval Toxocara cati), hookworms (adult and fourth-stage larval Ancylostoma tubaeforme, adult Ancylostoma braziliense), and tapeworms (adult Dipylidium caninum and Echinococcus multilocularis) in cats and kittens 7 weeks of age and older and weighing at least 1.8 lb. The topical medication is applied monthly and available by prescription only.

The effectiveness of Centragard was demonstrated in 18 controlled laboratory studies, with no adverse effects reported in any of the 226 cats administered the labeled dose. Study results indicate that Centragard is effective against induced heartworm infections after a single dose, as well as roundworms, hookworms, and tapeworms after a single dose or when given monthly as a preventive.

Click here for more information.

Mirataz: Feline Appetite Stimulant

Advertisement

Developed by California-based Kindred Biosciences, Mirataz (mirtazapine transdermal ointment) is intended for the management of weight loss in cats. It contains mirtazapine, a tetracyclic compound originally developed as an antidepressant for humans. Formulated with proprietary Accusorb technology, Mirataz is administered by applying a 1.5-in ribbon (about 2 mg) to the cat’s inner ear once daily for 14 days.

“This is the first and only drug approved by the FDA for this very serious condition,” KindredBio CEO Richard Chin said. “Not only that, but it is the first transdermal drug for cats approved by the FDA ever.”

Click here for more information.

Semintra: Systemic Hypertension Control

Available in Europe since 2013, Semintra (telmisartan oral solution) has become the first FDA-approved drug to control systemic hypertension in cats. With a highly targeted mode of action, Semintra provides rapid and reliable reduction in proteinuria in cats with chronic kidney disease. The drug’s active ingredient is telmisartan, an angiotensin II receptor blocker that reduces blood pressure by relaxing blood vessels. According to study results, the drug is well tolerated in cats (>90%), with its excretion almost exclusively independent of kidney function.

Marketed by Boehringer Ingelheim, Semintra is dosed twice daily for 14 days at 1.5 mg/kg and then decreased to once daily at 2.0 mg/kg. The oral solution can be administered either directly into the cat’s mouth or on top of a small amount of food.

Click here for more information.

download issueDownload Issue: July 2018

Related Content:

July 2018
website logo
The Information Revolution: We Can All Benefit
website logo
Antibiotic Selection in Pyoderma
website logo
Code Green: The Risk From Toxic Household Plants

Advertisement

Latest News

Drug for acute onset of canine pancreatitis is launched on the US market

New Automatic 2-in-1 Pet Feeder and Water Dispenser launched

PetHub launches AI tools for pet owners

Prairie dog pups emerge from underground at Maryland Zoo

View More Latest News
Advertisement